Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Clinical trial NCT07092514 · RECRUITING
Trial details
- NCT number
- NCT07092514
- Sponsor
- Washington University School of Medicine
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-14
- Primary completion
- 2029-04-17
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.